A U.S. House spending committee advanced language that would require a ban on using Chinese clinical trial data in future FDA drug applications, signaling deep congressional concerns about competition and data integrity. While the measure is unlikely to be adopted as written, its movement through committee reinforces pressure on regulators and sponsors to revisit how evidence from China is accepted in the U.S. review process. The proposal adds to an emerging U.S. policy environment where data origin and verification are increasingly central to oncology, rare disease, and specialty drug submissions.